Trial site
Institut de Cancérologie Lucien Neuwirth
- 14running trials
- 10closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Conditions
- Bladder cancer4 trials
- Prostate cancer4 trials
- Metastatic breast cancer3 trials
- Myelodysplastic syndromes3 trials
- Acute myeloid leukaemia2 trials
- Chronic lymphocytic leukaemia2 trials
- Colorectal cancer2 trials
- Lung cancer2 trials
- Myeloproliferative neoplasms2 trials
- Chronic myeloid leukaemia1 trial
- Head and neck cancer1 trial
- Ovarian cancer1 trial
- and 1 more
- Phase
- Phase 29 trials
- Phase 36 trials
- Phase 2/31 trial
- Status
- Active, not recruiting11 trials
- Completed8 trials
- Not yet recruiting2 trials
- Recruiting1 trial
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- UNICANCER5 trials
- Centre Leon Berard2 trials
- French Innovative Leukemia Organisation2 trials
- Groupe Francophone des Myelodysplasies2 trials
- AGO Research GmbH1 trial
- and 12 more
Running trials
Recruiting
Active, not recruiting
Active, not recruiting
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence
Active, not recruiting
Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)
Active, not recruiting
Recruiting
LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
Active, not recruiting
Active, not recruiting
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
Active, not recruiting
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Bladder cancer1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Prostate cancer1 recruiting
Closed trials
Completed
Completed
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Completed
Completed
Completed
Completed
Withdrawn
Completed
Completed
Terminated
Site data: ClinicalTrials.govUpdated 12 Nov 2026